At Lumito’s Scientific Advisory Board (SAB) meeting held on June 9, the SAB confirmed the uniqueness and potential of Lumito’s innovative solution, Scizys, for quantitative tissue analysis. Additionally, the advisors were unified in the view that Lumito has a product that will meet the needs of the pharmaceutical industry.

The SAB, where a few have had direct previous experience with nanoparticles, concluded that Lumitos nanoparticle technology has solved most of the issues experienced in the past. Lumitos nanoparticles demonstrate physical properties and characteristics that make the technology reliable and effective. In addition, the SAB concluded that the absence of disturbing autofluorescence from the tissue itself is a significant advantage in preclinical and clinical applications.

An area that was also discussed and highlighted in SAB was the potential of Lumito’s solution, due to its high accuracy and no autofluorescence from the tissue, to provide cleaner data sets. This can lead to better training of AI algorithms, improving biomarker development and ultimately ensuring that the right patients receive the right treatment.

“Having the opportunity to get in-depth discussions with these experts, and to get their honest view on our technology, solution, and overall business was extremely valuable. The board’s affirmation of our product is an important step in our commercial journey,” comments Sanna Wallenborg, CEO at Lumito.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

Attachments
Further Insights from Scientific Advisory Board Meeting - Confirms the Potential of Lumito's Innovative Solution for Quantitative Tissue Analysis

Läs mer på MFN